Letter to the Editor regarding: "Lipid-lowering therapy in patients with hypercholesterolemia in terms of the POLSCORE and SCORE2 scales. A single-center retrospective analysis".
I read with great interest the study by Rogozik et al. [1], which demonstrated that cardiovascular risk assessed using SCORE2 was substantially higher than that estimated with Pol-SCORE in patients with hypercholesterolemia without established cardiovascular disease. Through risk reclassification and comparisons of treatment status between the two scoring systems, the authors further showed that many individuals classified as high or very high risk by SCORE2 were discharged without lipid-lowerin...